Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription elongation factor A like 2 (TCEAL2)
- Target
- TCEAL2
- Molecular classification
- Transcription factor, Nuclear phosphoprotein, TCEAL gene family
01
Overview
Transcription elongation factor A like 2 (TCEAL2) is a nuclear phosphoprotein and a member of the TCEAL gene family, located on Xq22.1. It modulates transcription in a promoter context-dependent manner, contains transcription factor A domains, and is mainly localized to nuclear speckles and cytosol. TCEAL2 functions primarily in transcriptional regulation and is implicated as a tumor suppressor; it is downregulated in numerous malignancies, including ovarian and renal cancers. Its biological functions extend to synaptic vesicle localization, cognition, and axonal transport, and it binds tau protein as well as WW domains. TCEAL2 is positively associated with immune cell infiltration, particularly natural killer (NK) cells, and its methylation status serves as a biomarker for cancer prognosis. Disease associations include several cancers and amelogenesis imperfecta. Currently, there are no well-established drugs that directly target TCEAL2, nor defined mechanisms of action for such therapeutics[1][2][3].
- Other names
- Transcription elongation factor A protein-like 2TCEA-like protein 2transcription elongation factor A (SII)-like 2transcription elongation factor S-II protein-like 2My048MY0876G05WEX1my048MY0876G0
02
Biological functions
Modulates transcription in a promoter context-dependent mannerTranscriptional regulationTumor suppression (inhibits cell proliferation and induces cell cycle arrest in S phase)Synaptic vesicle localizationCognitionAxonal transportTau protein bindingWW domain binding (potential role in transcription, splicing, ubiquitination, cell growth, proliferation, differentiation, apoptosis)
03
Disease associations
Cancer (downregulated in multiple cancers including ovarian, renal, bladder, breast, colon, esophageal, oral, testicular germ cell tumors)Prognostic biomarker for poor prognosis in several cancers (e.g., ovarian)Amelogenesis imperfecta (genetic disease)Possibly involved in neurodegenerative processes (through tau protein interaction)
04
Biomarkers
Prognostic biomarker in cancers (level of TCEAL2 expression and promoter methylation are correlated with clinical outcomes)
Beyond the preview
Go deeper on Transcription elongation factor A like 2 (TCEAL2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transcription elongation factor A like 2 (TCEAL2).